SCHEMBL5744597

SCHEMBL5744597

COc1ccc(-c2ccc3c(c2)NC(=O)C2CNCCN32)c(C)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 16/20 0.50
HTR2A P28223 5/20 0.49
ALDH1A1 P00352 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTR2B P41595 5/20 0.45
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
MCHR1 Q99705 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11453721 0.81 HTR2C (0.67) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL5748262 0.81 HTR2C (0.52) HTR2CHTR2AHTR2BHTR3EHTR3B
SCHEMBL11453712 0.77 HTR2C (0.65) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL5743636 0.74 SCN5A (0.46)
SCHEMBL11445688 0.73 HTR2C (0.71) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL30857592 0.72 HSD17B10 (0.72) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL29114173 0.72 HTR2C (0.60) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL11455825 0.72 HTR2C (0.81) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL11481472 0.72 HTR2C (0.65) HTR2CHTR2AALDH1A1CYP1A2CYP3A4
SCHEMBL15307687 0.70 HTR2C (0.81) HTR2CHTR2AALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1345942-B9 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-11-15 EP disclosed
EP-1345942-B1 PYRAZINOQUINOXALINE DERIVATIVES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB PHARMA CO (US) 2006-03-01 EP disclosed
US-6638934-B2 2,3,4,4a,5,6-hexahydro-1H-pyrazino(1,2-a)quinoxaline derivatives; treating depression, schizophrenia; (5-hydroxytryptamine=5HT) 5HT2a antagonist or a 5HT2c agonist BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-10-28 US disclosed
US-20020177596-A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177596-A1 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands HTR1A, HTR5A, HTR1D HTR2C 6/4885HTR2A 10/4885ALDH1A1 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.